Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
Authors
Moore, James VWaller, Michael L
Zhao, Sha
Dodd, Nicholas J F
Acton, P D
Jeavons, A P
Hastings, D L
Affiliation
Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.Issue Date
1998-09
Metadata
Show full item recordAbstract
One early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.Citation
Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. 1998, 25 (9):1248-54 Eur J Nucl MedJournal
European Journal of Nuclear MedicineDOI
10.1007/s002590050292PubMed ID
9724373Type
ArticleLanguage
enISSN
0340-6997ae974a485f413a2113503eed53cd6c53
10.1007/s002590050292
Scopus Count
Related articles
- Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
- Authors: Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL
- Issue date: 2003 Oct 1
- High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.
- Authors: Lapointe D, Brasseur N, Cadorette J, La Madeleine C, Rodrigue S, van Lier JE, Lecomte R
- Issue date: 1999 May
- Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
- Authors: Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J
- Issue date: 2000
- Deciphering PDT-induced inflammatory responses using real-time FDG-PET in a mouse tumour model.
- Authors: Cauchon N, Hasséssian HM, Turcotte E, Lecomte R, van Lier JE
- Issue date: 2014 Oct
- In vivo magnetic resonance imaging of the effects of photodynamic therapy.
- Authors: Dodd NJ, Moore JV, Poppitt DG, Wood B
- Issue date: 1989 Aug